X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The financing will advance the clinical development of radiopharmaceuticals for the treatment of prostate cancer and other solid tumors, including its lead program with CONV01-α (actinium-J591), a monoclonal antibody conjugated to actinium-225, for advanced prostate cancer.
Lead Product(s): Actinium-J591
Therapeutic Area: Oncology Product Name: CONV01-alpha
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: OrbiMed
Deal Size: $90.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing May 03, 2023
Details:
The agreement will support Convergent's pipeline of next-generation radiotherapies including its lead asset, CONV01-α (225Ac−Rosopatamab), a prostate-specific membrane antigen (PSMA)-targeted monoclonal antibody linked to Ac-225.
Lead Product(s): 225Ac−rosopatamab,177Lu-PSMA-I&T,68Ga-PSMA-11
Therapeutic Area: Oncology Product Name: CONV01-alpha
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Ionetix
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement May 25, 2022
Details:
Under terms of the agreement, NorthStar will provide Convergent with its, high purity non-carrier-added Ac-225. Convergent will use NorthStar’s Ac-225 to radiolabel its lead asset, CONV01-α, a prostate-specific membrane antigen targeted monoclonal antibody.
Lead Product(s): 225Ac−Rosopatamab
Therapeutic Area: Oncology Product Name: CONV01-α
Highest Development Status: UndisclosedProduct Type: Large molecule
Partner/Sponsor/Collaborator: NorthStar Medical Radioisotopes
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement March 09, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
